Dr. Shivakumar Narayanan, MD

Infectious Disease (Infectious Disease Physician)

Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas

Medicare participating

Years since graduation: 20
In the NPI registry since: 2008
Medicare patients seen, 2024: 110

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

Infectious Disease Physician primary
MD license D82080
Internal Medicine Physician
MD license D82080

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Infectious Disease per capita by county →

Where they work

Hospitals

University of Maryland Medical Center Baltimore, MD
University of MD Medical Center Midtown Campus Baltimore, MD

Medical groups

University of Maryland Physicians PA (404 clinicians)

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024: 110
Services billed: 241
Patients’ average age: 69

Most frequent Medicare services, 2023
Service	Times	Patients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	128	61
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	56	55
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	38	25
Established patient office or other outpatient visit, 30-39 minutes	18	12
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	15	15

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
Drug	Prescriptions
Biktarvy (bictegrav/emtricit/tenofov ala)	88
Tamsulosin Hcl Other prescribers in Baltimore, MD	37
Dovato (dolutegravir sodium/lamivudine)	36
Atorvastatin Calcium Other prescribers in Baltimore, MD	33
Rosuvastatin Calcium Other prescribers in Baltimore, MD	30
Losartan Potassium Other prescribers in Baltimore, MD	30
Amlodipine Besylate Other prescribers in Baltimore, MD	24
Celecoxib Other prescribers in Baltimore, MD	15
Levetiracetam Other prescribers in Baltimore, MD	15
Creon (lipase/protease/amylase) Other prescribers in Baltimore, MD	13

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $93,082 in research payments for these studies, mostly to the institutions running them.

SUST054
Becton, Dickinson and Company
A phase 3B, open label, randomized, standard-of-care control arm, mult
Viiv Healthcare Company
SUST046
Becton, Dickinson and Company
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
Melinta Therapeutics, LLC · Terminated · NCT05521880

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

At a glance